Stoke Therapeutics, Inc. (STOK)

11.87 -0.15 (-1.25%) 收市：04:00PM EDT

Stoke Therapeutics, Inc.

45 Wiggins Avenue
Bedford, MA 01730
United States
781 430 8200
https://www.stoketherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 110

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Edward M. Kaye M.D., Ph.D.	CEO & Director	948.9k	無	1949
Dr. Adrian R. Krainer Ph.D.	Co-Founder & Independent Director	44k	無	1959
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Chief Medical Officer	684.55k	無	1961
Ms. Isabel Aznarez Ph.D.	Co-Founder & Group VP of Discovery Research	無	無	1973
Dr. Huw M. Nash Ph.D.	COO & Chief Business Officer	429.67k	無	1967
Mr. Eric Rojas	Head of Investor Relations	無	無	無
Mr. Jonathan Allan J.D.	Corporate Secretary & General Counsel	無	無	1990
Ms. Dawn Kalmar	Chief Communications Officer	無	無	1978
Ms. Joan Wood	Chief Human Resources Officer	無	無	無
Ms. Shamim Ruff M.S.	Chief Regulatory Officer	無	無	1960

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

公司管治

截至 2024年5月1日 止，Stoke Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。